Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Method for treating neurodegenerative diseases
US10272070B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10272070-B2 |
| Application number | US-201515518438-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 14, 2015 |
| Priority date | Oct 14, 2014 |
| Publication date | Apr 30, 2019 |
| Grant date | Apr 30, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of suppressing microglia-mediated inflammation in a subject diagnosed with a neurodegenerative disease, comprising the step of administering to a subject suffering from a neurodegenerative disease an effective amount of 2-(4-tert-butylphenyl)-1H-benzimidazole. 2. The method of claim 1 , wherein the neurodegenerative disease is selected from the group consisting of: amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, and a demyelinating disease. 3. The method according to claim 1 , wherein said compound is administered by systemic administration. 4. The method according to claim 1 , wherein said compound is administered by oral administration. 5. The method of claim 2 , wherein the neurodegenerative disease is ALS. 6. The method of claim 2 , wherein the neurodegenerative disease is Alzheimer's disease. 7. The method of claim 2 , wherein the neurodegenerative disease is Parkinson's disease. 8. The method of claim 2 , wherein the neurodegenerative disease is Huntington's disease. 9. The method of claim 2 , wherein the neurodegenerative disease is frontotemporal degeneration. 10. The method of claim 2 , wherein the neurodegenerative disease is dementia with Lewy bodies. 11. The method of claim 2 , wherein the neurodegenerative disease is a motor neuron disease. 12. The method of claim 2 , wherein the neurodegenerative disease is a demyelinating disease. 13. The method of any one of claims 5 - 12 , wherein said compound is administered by systemic administration. 14. The method of any one of claims 5 - 12 , wherein said compound is administered by oral administration.
Assignees
Inventors
Classifications
- A61K31/4184Primary
condensed with carbocyclic rings, e.g. benzimidazoles · CPC title
having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title
Medicinal preparations containing organic active ingredients · CPC title
with aryl radicals directly attached in position 2 · CPC title
of the sugar · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10272070B2 cover?
- The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-…
- Who is the assignee on this patent?
- Univ Leland Stanford Junior, The Board Of Trustees Of The Leland Stanford Junio R Univ
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4184. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).